Kyowa Kirin Co Ltd
TSE:4151
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 268
3 325
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kyowa Kirin Co Ltd
Operating Margin
Kyowa Kirin Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | JP |
| Market Cap | 1.3T JPY |
| Operating Margin |
20%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Operating Margin |
-83%
|
| Country | US |
| Market Cap | 755.8B USD |
| Operating Margin |
35%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Operating Margin |
3%
|
| Country | DK |
| Market Cap | 2.7T DKK |
| Operating Margin |
44%
|
| Country | US |
| Market Cap | 351.1B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 251.8B USD |
| Operating Margin |
34%
|
| Country | CH |
| Market Cap | 200.1B CHF |
| Operating Margin |
32%
|
| Country | UK |
| Market Cap | 161.8B GBP |
| Operating Margin |
21%
|
| Country | CH |
| Market Cap | 171.5B CHF |
| Operating Margin |
31%
|
| Country | US |
| Market Cap | 151.5B USD |
| Operating Margin |
22%
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Kyowa Kirin Co Ltd's most recent financial statements, the company has Operating Margin of 20.1%.
You don't have any saved screeners yet
